Tutogen Medical and Mentor Enter Into Exclusive Distribution Agreement for Breast Reconstruction Market
June 29 2006 - 11:00AM
PR Newswire (US)
Mentor Will Have the Exclusive North American Rights for Tutoplast
Dermis ALACHUA, Fla., June 29 /PRNewswire-FirstCall/ -- Tutogen
Medical, Inc., (AMEX:TTG), a leading manufacturer of sterile
biological implant products made from human (allograft) and animal
(xenograft) tissue, today announced that it has entered into a
distribution agreement with Mentor Corporation, a leader in the
breast implant and aesthetic product markets. Mentor will have the
exclusive North American rights for the use of Tutoplast Dermis in
the dermatology and plastic surgery markets for breast
reconstruction. Tutogen will be receiving an upfront payment in
consideration for these distribution rights. Guy Mayer, Chief
Executive Officer of Tutogen, commented, "We are excited to be
partnering with Mentor in this important market. The Tutoplast
processed grafts complement Mentor's implant products for breast
reconstruction following mastectomy or injury. We are pleased to be
helping women regain their natural profile and confidence following
these difficult events." About Tutogen Medical, Inc. Tutogen
Medical, Inc. manufactures sterile biological implant products made
from human (allograft) and animal (xenograft) tissue. Tutogen
utilizes its Tutoplast Process(R) of tissue preservation and viral
inactivation to manufacture and deliver sterile bio-implants used
in spinal/trauma, urology, dental, ophthalmology, and general
surgery procedures. The Company's Tutoplast(R) products are sold
and distributed worldwide by Zimmer Spine and Zimmer Dental,
subsidiaries of Zimmer Holdings, Inc. the Mentor Corporation, IOP,
Inc. and through independent distributors and subsidiaries in the
U.S. and Germany. For more information, visit the Company's Web
site at http://www.tutogen.com/ . Forward-Looking Statement
Disclaimer: Certain statements in this news release are
forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such
statements involve risks and uncertainties, which may differ
materially from those set forth in these statements, including the
status of the Company's listing on the American Stock Exchange and
the anticipated timing for restatement of the Company's financial
statements. Forward-looking statements are based on management's
current expectations and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those set forth or implied by forward-looking statements.
These and other risks are identified in the Company's filings with
the Securities and Exchange Commission, including the Company's
Annual Report on Form 10-K for the fiscal year ended September 30,
2005. All information in this press release is as of the date
hereof, and the Company undertakes no duty to update this
information unless required by law. Contacts: L. Robert Johnston,
CFO Lytham Partners, LLC Tutogen Medical, Inc. Institutional: Joe
Diaz 386-462-0402 Retail: Joe Dorame 602-889-9700 DATASOURCE:
Tutogen Medical, Inc. CONTACT: L. Robert Johnston, CFO of Tutogen
Medical, Inc., +1-386-462-0402, ; or Institutional, Joe Diaz, or
Retail, Joe Dorame, both of Lytham Partners, LLC, +1-602-889-9700,
for Tutogen Medical, Inc. Web site: http://www.tutogen.com/
Copyright
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From May 2024 to Jun 2024
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Jun 2023 to Jun 2024